Showing results (291-300 of 371) with videos related to

Sort By:
Pageof 38
Gynecologic Oncology|March 24, 2007
HLA-DQB1 polymorphisms and risk for cervical cancer: a case-control study in a southern Chinese populationPaul K S Chan, Jo L K Cheung, Tak-Hong Cheung, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 14, 2020
Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage-myofibroblast transitionPatrick Ming-Kuen Tang, Ying-Ying Zhang, Jun Xiao, et al.
Cancer Medicine|June 26, 2024
The establishment of kidney cancer organoid line in drug testingRyan Tsz-Hei Tse, Christine Yim-Ping Wong, Xiaofan Ding, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2012
Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cellsChi Man Tsang, Yim Ling Yip, Kwok Wai Lo, et al.
Cell|January 31, 2024
Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in miceKaili Fu, Alvin Ho Kwan Cheung, Chi Chun Wong, et al.
Gut|December 25, 2025
Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinomaYasi Pan, Xiang Zhang, Chi Chun Wong, et al.
Oncotarget|December 20, 2015
TGF-β/Smad3 signalling regulates the transition of bone marrow-derived macrophages into myofibroblasts during tissue fibrosisShuang Wang, Xiao-Ming Meng, Yee-Yung Ng, et al.
Molecular Cancer|July 25, 2018
RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancerYi Pan, Joanna Hung Man Tong, Raymond Wai Ming Lung, et al.
Nature Communications|July 8, 2022
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancerChi Chun Wong, Jian-Lin Wu, Fenfen Ji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, et al.
Pageof 38